Free Trial

Invizyne Technologies (IZTC) Competitors

Invizyne Technologies logo
$9.81 -0.21 (-2.10%)
As of 07/11/2025

IZTC vs. IMMP, FENC, EDIT, SOPH, MNPR, ESPR, PRQR, SLRN, CGC, and TVGN

Should you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Prima BioMed (IMMP), Adherex Technologies (FENC), Editas Medicine (EDIT), SOPHiA GENETICS (SOPH), Monopar Therapeutics (MNPR), Esperion Therapeutics (ESPR), ProQR Therapeutics (PRQR), Acelyrin (SLRN), Canopy Growth (CGC), and Semper Paratus Acquisition (TVGN). These companies are all part of the "pharmaceutical products" industry.

Invizyne Technologies vs. Its Competitors

Prima BioMed (NASDAQ:IMMP) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

2.3% of Prima BioMed shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Prima BioMedN/A N/A N/A
Invizyne Technologies N/A N/A N/A

Invizyne Technologies has lower revenue, but higher earnings than Prima BioMed.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prima BioMed$5.14M46.88-$28.01MN/AN/A
Invizyne TechnologiesN/AN/AN/AN/AN/A

In the previous week, Prima BioMed had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Prima BioMed and 0 mentions for Invizyne Technologies. Prima BioMed's average media sentiment score of 1.87 beat Invizyne Technologies' score of 0.63 indicating that Prima BioMed is being referred to more favorably in the media.

Company Overall Sentiment
Prima BioMed Very Positive
Invizyne Technologies Positive

Prima BioMed currently has a consensus price target of $7.00, suggesting a potential upside of 324.24%. Given Prima BioMed's stronger consensus rating and higher possible upside, research analysts plainly believe Prima BioMed is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prima BioMed
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Prima BioMed beats Invizyne Technologies on 8 of the 8 factors compared between the two stocks.

Get Invizyne Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IZTC vs. The Competition

MetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$61.33M$209.58M$5.60B$9.10B
Dividend YieldN/AN/A5.24%4.00%
P/E RatioN/AN/A27.9620.25
Price / SalesN/A253.11429.2099.14
Price / CashN/A22.4437.4658.16
Price / BookN/A6.158.045.49
Net IncomeN/A-$96.61M$3.18B$250.27M
7 Day Performance-1.01%12.45%3.63%4.75%
1 Month Performance-25.40%10.71%4.04%7.64%
1 Year PerformanceN/A6.49%29.56%16.34%

Invizyne Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IZTC
Invizyne Technologies
N/A$9.81
-2.1%
N/AN/A$61.33MN/A0.0029Gap Down
IMMP
Prima BioMed
1.5157 of 5 stars
$1.70
+1.2%
$7.00
+311.8%
-17.9%$248.27M$5.14M0.002,021
FENC
Adherex Technologies
2.1873 of 5 stars
$8.70
+2.7%
$13.00
+49.4%
+34.5%$240.12M$47.54M-17.0610News Coverage
Analyst Upgrade
EDIT
Editas Medicine
4.2751 of 5 stars
$2.86
+12.6%
$4.70
+64.3%
-47.3%$239.41M$32.31M-0.94230High Trading Volume
SOPH
SOPHiA GENETICS
2.7371 of 5 stars
$3.56
+9.5%
$7.00
+96.6%
-25.9%$237.42M$65.17M-3.56520Positive News
MNPR
Monopar Therapeutics
2.0323 of 5 stars
$38.37
+3.1%
$60.00
+56.4%
+924.0%$234.82MN/A-11.0310Analyst Revision
ESPR
Esperion Therapeutics
4.0385 of 5 stars
$1.17
+5.4%
$7.00
+498.3%
-52.2%$231.89M$332.31M-1.46200News Coverage
Analyst Revision
PRQR
ProQR Therapeutics
2.576 of 5 stars
$2.20
+2.8%
$8.00
+263.6%
+34.1%$231.46M$20.46M-6.29180Analyst Forecast
SLRN
Acelyrin
N/A$2.27
flat
$9.60
+322.9%
N/A$229.17MN/A-0.92135
CGC
Canopy Growth
0.4091 of 5 stars
$1.23
+2.5%
$2.00
+62.6%
-82.6%$226.16M$225.65M-0.303,150High Trading Volume
TVGN
Semper Paratus Acquisition
4.0446 of 5 stars
$1.22
+1.7%
$10.00
+719.7%
+70.0%$224.35MN/A0.003

Related Companies and Tools


This page (NASDAQ:IZTC) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners